- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03206918
Efficacy and Safety of Zanubrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
September 29, 2021 updated by: BeiGene
A Single-Arm, Open-Label, Multicenter Phase 2 Study to Evaluate Safety and Efficacy of BGB-3111, a Bruton's Tyrosine Kinase (BTK) Inhibitor in Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
This was a single-arm, open-label, multi-center Phase 2 study in participants with histologically documented CLL/SLL who have relapsed after or refractory to ≥ 1 prior treatment regimen(s).
The study is composed of an initial screening phase, a single-arm treatment phase, and a follow-up phase.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
91
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Beijing
-
Beijing, Beijing, China, 100730
- Peking Union Medical College Hospital
-
Beijing, Beijing, China, 100082
- Peking University People's Hospital
-
-
Fujian
-
Fuzhou, Fujian, China, 350001
- Fujian Medical University Union Hospital
-
-
Guangdong
-
Guangzhou, Guangdong, China, 510515
- Nanfang Hospital
-
-
Guangxi
-
Nanning, Guangxi, China
- The First Affiliated Hospital of Guangxi Medical University
-
-
Guangzhou
-
Guangdong, Guangzhou, China
- Guangdong Provincial People's Hospital
-
-
Henan
-
Zhengzhou, Henan, China, 450008
- Henan Cancer Hospital
-
-
Hubei
-
Wuhan, Hubei, China, 430030
- Tongji Hospital of Tongji Medical College of HUST
-
-
Jiangsu
-
Nanjing, Jiangsu, China, 210029
- Jiangsu Province Hospital
-
Suzhou, Jiangsu, China, 215006
- The First Affiliated Hospital Of Soochow University
-
-
Jinlin
-
Changchun, Jinlin, China, 130021
- The First Affilliated Hospital of Jinlin University
-
-
Shanghai
-
Shanghai, Shanghai, China
- Ruijin Hospital Shanghai JiaoTong University School of Medicine
-
-
Shanxi
-
Xi'an, Shanxi, China
- The First Affiliated Hospital of Xi 'an Jiaotong University
-
-
Sichuan
-
Chengdu, Sichuan, China, 610041
- West China Hospital of Sichuan University
-
-
Tianjin
-
Tianjin, Tianjin, China, 300020
- Tianjin Hematonosis Hospital
-
-
Zhejiang
-
Hangzhou, Zhejiang, China
- The First Affiliated Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Key Inclusion Criteria:
- Confirmed diagnosis with at least one criterion for treatment according to International workshop on chronic lymphocytic leukemia (IWCLL)
- Eastern Cooperative Oncology Group (ECOG) performance status of 0-2
- Measurable disease by contrast enhanced computerized tomography / magnetic resonance imaging (CT/MRI).
- Previously treated with a minimum of 1 prior line of standard chemotherapy-containing regimen (with completion of ≥2 treatment cycles).
- Documented failure to achieve at least partial response (PR) or documented disease progression after response to the most recent treatment regimen. Refractory disease is defined as treatment failure (stable disease, non-response, progressive disease [PD]) or disease progression within 6 months after the most recent prior therapy (Hallek et al, 2008).
- Neutrophils ≥ 0.75 x 109/L independent of growth factor support within 7 days of study entry
- Platelets ≥ 50 x 109/L, independent of growth factor support or transfusion within 7 days of study entry
- Creatinine clearance of ≥ 30 ml/min (as estimated by the Cockcroft-Gault equation or estimated glomerular filtration rate [eGFR] from the Modification of Diet in Renal Disease [MDRD])
- Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤3 x ULN
- Bilirubin ≤2 x ULN (unless documented Gilbert's syndrome)
- International normalized ratio (INR) ≤1.5 and activated partial thromboplastin time (APTT) ≤1.5 x ULN.
- Participants may be enrolled who relapse after autologous stem cell transplant if they are at least 6 months after transplant.
- Life expectancy of >4 months
- Echocardiogram (ECHO) must demonstrate left ventricular ejection fraction (LVEF) ≥50%; (AHA, 2016)
Key Exclusion Criteria:
- Current or history of central nervous system (CNS) lymphoma
- Prior exposure to a Bruton's tyrosine kinase (BTK) inhibitor
- Prior corticosteroids given in excess of prednisone 10 mg/day or its equivalent with antineoplastic intent within 7 days.
- Major surgery within 4 weeks of screening
- Not recovered from toxicity of any prior anti-cancer therapy to <Grade 1 (except for alopecia, absolute neutrophil count (ANC) and platelets.
- History of other active malignancies within 2 years of study entry, with exception of (1) adequately treated in-situ carcinoma of cervix; (2) localized basal cell or squamous cell carcinoma of skin; (3) previous malignancy confined and treated locally (surgery or other modality) with curative intent
- Currently active clinically significant cardiovascular disease
- QTcF >480 msecs based on Fridericia's formula or other significant electrocardiogram abnormalities including second degree atrioventricular (AV) block Type II, or third degree AV block
- Unable to swallow capsules or disease significantly affecting gastrointestinal function such as malabsorption syndrome, resection of the stomach or small bowel, symptomatic inflammatory bowel disease, or partial or complete bowel obstruction
- Active infection including infections requiring oral or intravenous anti-microbials
- Known human immunodeficiency virus (HIV), or active hepatitis B or hepatitis C infection (detected positive by polymerase chain reaction [PCR]).
- Has received allogenic hematopoietic stem cell transplantation prior to enrollment
- Any life-threatening illness, medical condition or organ system dysfunction which, in the investigator's opinion, could compromise the participants's safety, or put the study at risk
- Requires ongoing treatment with any medication which is a strong cytochrome P450, family 3, subfamily A (CYP3A) inhibitor or strong CYP3A inducer
- Known or clinically suspected Richter's transformation at the time of study entry
- History of stroke or intracranial hemorrhage within 6 months prior to enrollment
NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Zanubrutinib
|
Zanubrutinib 160 mg (two - 80 mg white opaque capsules) taken by mouth (PO) twice a day (BID)
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall Response Rate (ORR) by Independent Review Committee (IRC)
Time Frame: Up to 1 year and 4 months
|
ORR is defined as the number of participants who achieve a best response of CR or, CRi, Nodular Partial Response, PR, and PR with Lymphocytosis as assessed by IRC per the modified IWCLL Guidelines in participants with CLL and the Revised Criteria for Response for Malignant Lymphoma in participants with SLL.
|
Up to 1 year and 4 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Progression-free Survival (PFS): Percentage of Participants Progression/Death Event Free
Time Frame: 6, 12, 24, and 36 months
|
PFS is defined as the time from treatment initiation to first documentation of progression by International workshop on chronic lymphocytic leukemia (IWCLL) criteria/revised criteria for response for malignant lymphoma or death, whichever is earlier.
|
6, 12, 24, and 36 months
|
Duration of Response (DOR): Event Free Rate - Percentage of Participants Who Remained Event Free
Time Frame: 6, 12, 24, and 36 months
|
DOR is defined as the time from the date that response criteria are first met to the date that progressive disease (PD) is objectively documented or death, whichever occurs first
|
6, 12, 24, and 36 months
|
Time to Response (TTR)
Time Frame: Up to 3.5 years
|
TTR is defined as the time from treatment initiation to first signs of response
|
Up to 3.5 years
|
Overall Response Rate as Determined by the Investigator
Time Frame: up to 3.5 years
|
Overall response was defined as achieving a best overall response of CR, CRi, nodular partial response (nPR), PR, or partial response with lymphocytosis (PR-L).
|
up to 3.5 years
|
Number of Participants Experiencing Adverse Events (AEs)
Time Frame: Up to 3.5 years
|
An adverse event (AE) was defined as any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.
All AEs were monitored per the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE version [v] 4.03 2010).
A treatment emergent adverse event (TEAE) is defined as an adverse event that has an onset date or a worsening in severity from baseline (pretreatment) on or after the date of first dose of study drug up to 30 days following study drug discontinuation or initiation of new anticancer therapy, whichever occurs first.
|
Up to 3.5 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Xu W, Yang S, Tam CS, Seymour JF, Zhou K, Opat S, Qiu L, Sun M, Wang T, Trotman J, Pan L, Gao S, Zhou J, Zhou D, Zhu J, Song Y, Hu J, Feng R, Huang H, Su D, Shi M, Li J. Zanubrutinib Monotherapy for Naive and Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: A Pooled Analysis of Three Studies. Adv Ther. 2022 Sep;39(9):4250-4265. doi: 10.1007/s12325-022-02238-7. Epub 2022 Jul 28.
- Xu W, Yang S, Zhou K, Pan L, Li Z, Zhou J, Gao S, Zhou D, Hu J, Feng R, Huang H, Ji M, Guo H, Huang J, Novotny W, Feng S, Li J. Treatment of relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma with the BTK inhibitor zanubrutinib: phase 2, single-arm, multicenter study. J Hematol Oncol. 2020 May 11;13(1):48. doi: 10.1186/s13045-020-00884-4.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
March 9, 2017
Primary Completion (Actual)
June 15, 2018
Study Completion (Actual)
September 10, 2020
Study Registration Dates
First Submitted
June 29, 2017
First Submitted That Met QC Criteria
June 29, 2017
First Posted (Actual)
July 2, 2017
Study Record Updates
Last Update Posted (Actual)
October 4, 2021
Last Update Submitted That Met QC Criteria
September 29, 2021
Last Verified
September 1, 2021
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Immune System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Lymphoproliferative Disorders
- Lymphatic Diseases
- Immunoproliferative Disorders
- Leukemia, B-Cell
- Lymphoma
- Leukemia
- Leukemia, Lymphocytic, Chronic, B-Cell
- Leukemia, Lymphoid
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antineoplastic Agents
- Protein Kinase Inhibitors
- Zanubrutinib
Other Study ID Numbers
- BGB-3111-205
- CTR20160890 (Registry Identifier: ChinaDrugTrials.org)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Yes
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Relapsed or Refractory Chronic Lymphocytic Leukemia
-
Allogene TherapeuticsRecruitingRelapsed or Refractory Large B Cell Lymphoma, Relapsed or Refractory Chronic Lymphocytic Leukemia, Relapsed or Refractory Small Lymphocytic LymphomaUnited States, Spain, Canada, Australia, Italy
-
University Health Network, TorontoTakara Bio Inc.RecruitingRelapsed or Refractory Chronic Lymphocytic Leukemia | Relapsed or Refractory Small Lymphocytic Lymphoma | Relapsed or Refractory CD19+ B-cell LymphomaCanada
-
Virginia Commonwealth UniversityGilead SciencesWithdrawnChronic Lymphocytic Leukemia | Refractory Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma | CLL | Refractory Small Lymphocytic Lymphoma | SLL | Relapsed CLL | Relapsed Chronic Lymphocytic Leukemia | Relapsed Small Lymphocytic Lymphoma
-
AstraZenecaActive, not recruitingPhase I: Relapsed or Refractory B-cell Malignancies | Phase II Cohort A: Relapsed or Refractory Mantle Cell Lymphoma | Phase II Cohort B: Relapsed or Refractory Chronic Lymphocytic LeukemiaChina
-
Institut de Recherches Internationales ServierADIR, a Servier Group companyCompletedRelapsed or Refractory Multiple Myeloma | Relapsed or Refractory Acute Myeloid Leukemia | Relapsed or Refractory Non-Hodgkin Lymphoma | Relapsed or Refractory Chronic Lymphocytic LeukemiaUnited Kingdom, Spain, France, Australia
-
Kite, A Gilead CompanyTerminatedRelapsed/Refractory Chronic Lymphocytic Leukemia and Relapsed/Refractory Small Lymphocytic LymphomaUnited States, Italy
-
French Innovative Leukemia OrganisationJanssen, LPActive, not recruitingRelapsed or Refractory Chronic Lymphocytic LeukemiaFrance
-
CelgeneCompletedRelapsed or Refractory Chronic Lymphocytic LeukemiaUnited States, Canada, United Kingdom, France, Germany, Spain, Italy, Sweden
-
Novartis PharmaceuticalsTerminatedRelapsed or Refractory Chronic Lymphocytic Leukemia (CLL)Spain, United States
-
Pharmacyclics LLC.Janssen Research & Development, LLCCompletedRelapsed or Refractory Chronic Lymphocytic Leukemia | Small Lymphocytic LymphomaUnited States, Australia, Austria, Belgium, France, Ireland, Italy, Poland, Spain, United Kingdom
Clinical Trials on Zanubrutinib
-
Zhang Lei, MDRecruitingThrombocytopenia | Antiphospholipid Syndrome | TreatmentChina
-
Fudan UniversityRecruiting
-
Xuanwu Hospital, BeijingRecruitingNeuromyelitis OpticaChina
-
Zhang LeiRecruitingImmune Thrombocytopenia | TreatmentChina
-
Matthew C. BakerStanford UniversityRecruiting
-
Stichting Hemato-Oncologie voor Volwassenen NederlandNot yet recruitingLymphomaNorway, Netherlands, Denmark, Belgium
-
The First Affiliated Hospital of Soochow UniversityRecruitingUntreated Mantle Cell LymphomaChina
-
Fudan UniversityRecruitingMantle Cell Lymphoma | Maintenance TherapyChina
-
Fudan UniversityRecruitingDiffuse Large B-cell Lymphoma(DLBCL)China
-
Huazhong University of Science and TechnologyRecruitingDiffuse Large B Cell LymphomaChina